SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
02-Oct-23 4:37 PM View: | Dudley Robert Michael Chief Executive Officer Director | Transcode Therapeutics, Inc. (RNAZ) | 28-Sep-23 | Private Purchase | 98,000 | $0.51 | $49,980.00 | 119% 82.26K to 180.26K | |
02-Oct-23 4:39 PM View: | Fitzgerald Thomas A Chief Financial Officer Director | Transcode Therapeutics, Inc. (RNAZ) | 28-Sep-23 | Private Purchase | 49,350 | $0.51 | $25,168.50 | 708% 6.97K to 56.32K | |
22-Jun-23 6:23 PM View: | Dudley Robert Michael Chief Executive Officer Director | Transcode Therapeutics, Inc. (RNAZ) | 21-Jun-23 | Market Purchase | 12,000 | $2.65 | $31,818.00 | 17% 70.26K to 82.26K | (8%) |
22-Jun-23 6:23 PM View: | Dudley Robert Michael Chief Executive Officer Director | Transcode Therapeutics, Inc. (RNAZ) | 20-Jun-23 | Market Purchase | 6,607 | $2.55 | $16,846.50 | 10% 63.66K to 70.26K | (4%) |
13-Jun-23 4:16 PM View: | Dudley Robert Michael Chief Executive Officer Director | Transcode Therapeutics, Inc. (RNAZ) | 09-Jun-23 | Purchase | 19,000 | $2.76 | $52,440.00 | 2% 893.11K to 912.11K | |
16-Sep-22 6:44 PM View: | Dudley Robert Michael Chief Executive Officer Director 10% Owner | Transcode Therapeutics, Inc. (RNAZ) | 14-Sep-22 | Private Purchase | 20,000 | $1.15 | $23,000.00 | 2% 873.11K to 893.11K | |
17-Jun-22 4:01 PM View: | Fitzgerald Thomas A Chief Financial Officer Director | Transcode Therapeutics, Inc. (RNAZ) | 16-Jun-22 | Private Purchase | 12,000 | $1.27 | $15,240.00 | 9% 127.38K to 139.38K | |
01-Jun-22 4:01 PM View: | Dudley Robert Michael Chief Executive Officer Director 10% Owner | Transcode Therapeutics, Inc. (RNAZ) | 31-May-22 | Purchase | 2,000 | $1.87 | $3,739.80 | < 1% 871.11K to 873.11K | |
01-Jun-22 4:01 PM View: | Dudley Robert Michael Chief Executive Officer Director 10% Owner | Transcode Therapeutics, Inc. (RNAZ) | 27-May-22 | Private Purchase | 28,000 | $1.84 | $51,643.20 | 3% 843.11K to 871.11K |